Sam Chun Dang Pharm. Co., Ltd
000250
Rank in Stocks
#4333
Sam Chun Dang Pharm Co., Ltd. is a pharmaceutical company that develops and... Sam Chun Dang Pharm Co., Ltd. is a pharmaceutical company that develops and produces a wide variety of medications. Its product range features antibiotics, treatments for cardiovascular and respiratory conditions, drugs for the digestive system and ophthalmic use, as well as anti-inflammatory agents. The company was founded on December 29, 1943, and its main operations are based in Hwaseong-si, South Korea.
Share Price
$152.58
Market Cap
$3.57B
Change (1 day)
3.84%
Change (1 year)
6.02%
Country
KR
Trade Sam Chun Dang Pharm. Co., Ltd (000250)
Category
Healthcare
Earnings for Sam Chun Dang Pharm. Co., Ltd (000250)
Earnings in Jun 2026 TTM: $22.36M
According to Sam Chun Dang Pharm. Co., Ltd latest financial reports the company's current earnings are $22.36M. In 2024 the company made an earning of $7.51M, an increase over its 2023 earnings that were of $-3.44M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Sam Chun Dang Pharm. Co., Ltd from 2004 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $22.36M | 158.03% |
| 2025 | $8.66M | 15.41% |
| 2024 | $7.51M | -317.97% |
| 2023 | $-3.44M | -148.73% |
| 2022 | $7.07M | -142.99% |
| 2021 | $-16.44M | -207.66% |
| 2020 | $15.27M | -8.70% |
| 2019 | $16.73M | 28.81% |
| 2018 | $12.99M | -42.52% |
| 2017 | $22.59M | 20.24% |
| 2016 | $18.79M | 5.97% |
| 2015 | $17.73M | -3.02% |
| 2014 | $18.28M | 100.40% |
| 2013 | $9.12M | 61.18% |
| 2012 | $5.66M | -11.95% |
| 2011 | $6.43M | 3.66% |
| 2010 | $6.20M | 25.67% |
| 2009 | $4.94M | -24.16% |
| 2008 | $6.51M | -25.53% |
| 2007 | $8.74M | 151.00% |
| 2006 | $3.48M | -58.00% |
| 2005 | $8.29M | 0.61% |
| 2004 | $8.24M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $1.35B | 5,937.56% |
US
|
|
| $125.33M | 460.58% |
SE
|
|
| $787.12M | 3,420.56% |
FR
|
|
| $739.88M | 3,209.25% |
IT
|
|
| $26.37M | 17.94% |
US
|
